Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now.

Q4 2025 earnings call highlights: 2026 revenue outlook, ALYFTREK progress, CASGEVY/JOURNAVX growth, and renal pipeline—read ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

Revenue growth in 2025 was tempered by lower entitlement growth and a moderation in upsell/cross-sell activity compared to previous periods. Management attributed 2025 customer attrition primarily to ...

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

Vertex, Inc. (NASDAQ: VERX) ('Vertex” or the 'Company”), a leading global provider of indirect tax solutions, today announced ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager ...